Foresee Pharmaceuticals (6576.TWO) announced positive topline results from Phase 3 Casppian trial evaluating the efficacy and safety of FP-001 42 mg, an investigational, sustained-release GnRH agonist, administered every six months in children with Central Precocious Puberty. The company said the proportion of patients with serum luteinizing hormone suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically significant, which exceeded the pre-specified success criterion. FP-001 42 mg injection was well tolerated.
"Meeting this rigorous primary endpoint with such a high threshold of 94% is a significant milestone. It underscores the potential of FP-001 to offer a meaningful new treatment option, potentially improving convenience and adherence of children with CPP," said Bassem Elmankabadi, Senior Vice President, Clinical Development.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.